Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina.

Abstract:

:Spirulina is free-floating filamentous microalgae growing in alkaline water bodies. With its high nutritional value, Spirulina has been consumed as food for centuries in Central Africa. It is now widely used as nutraceutical food supplement worldwide. Recently, great attention and extensive studies have been devoted to evaluate its therapeutic benefits on an array of diseased conditions including hypercholesterolemia, hyperglycerolemia, cardiovascular diseases, inflammatory diseases, cancer, and viral infections. The cardiovascular benefits of Spirulina are primarily resulted from its hypolipidemic, antioxidant, and antiinflammatory activities. Data from preclinical studies with various animal models consistently demonstrate the hypolipidemic activity of Spirulina. Although differences in study design, sample size, and patient conditions resulting in minor inconsistency in response to Spirulina supplementation, the findings from human clinical trials are largely consistent with the hypolipidemic effects of Spirulina observed in the preclinical studies. However, most of the human clinical trials are suffered with limited sample size and some with poor experimental design. The antioxidant and/or antiinflammatory activities of Spirulina were demonstrated in a large number of preclinical studies. However, a limited number of clinical trials have been carried out so far to confirm such activities in human. Currently, our understanding on the underlying mechanisms for Spirulina's activities, especially the hypolipidemic effect, is limited. Spirulina is generally considered safe for human consumption supported by its long history of use as food source and its favorable safety profile in animal studies. However, rare cases of side-effects in human have been reported. Quality control in the growth and process of Spirulina to avoid contamination is mandatory to guarantee the safety of Spirulina products.

journal_name

Cardiovasc Ther

authors

Deng R,Chow TJ

doi

10.1111/j.1755-5922.2010.00200.x

subject

Has Abstract

pub_date

2010-08-01 00:00:00

pages

e33-45

issue

4

eissn

1755-5914

issn

1755-5922

pii

CDR200

journal_volume

28

pub_type

杂志文章,评审
  • Review: Nutriceuticals as antithrombotic agents.

    abstract::Thrombus formation in a disrupted endothelium is influenced not only by the platelet redox state and reactive oxygen and nitrogen species but also by the presence of endogenous or exogenous antioxidants. Thrombus formation in the stenotic arteries is triggered predominantly by attenuated shear stress. Superoxide and n...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00161.x

    authors: Chakrabarti S,Freedman JE

    更新日期:2010-08-01 00:00:00

  • Aspirin resistance and compliance with therapy.

    abstract:INTRODUCTION:Aspirin resistance is associated with increased cardiovascular risk in aspirin-treated patients. Poor compliance may explain many cases of "resistance," yet few clinical studies have used objective measurement of therapy compliance. We did so in a case-controlled study. METHODS:We enrolled patients within...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00188.x

    authors: Dawson J,Quinn T,Rafferty M,Higgins P,Ray G,Lees KR,Walters MR

    更新日期:2011-10-01 00:00:00

  • Diagnosis and management of atrial fibrillation: an overview.

    abstract::Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12090

    authors: Romero I,Nedios S,Kriatselis C

    更新日期:2014-10-01 00:00:00

  • The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.

    abstract:BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00203.x

    authors: Kloner RA,Dow JS,Bhandari A

    更新日期:2011-08-01 00:00:00

  • Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japane

    abstract:BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12027

    authors: Kawashiri MA,Yamagishi M,Sakamoto T,Takayama T,Hiro T,Daida H,Hirayama A,Saito S,Yamaguchi T,Matsuzaki M,COSMOS Investigators.

    更新日期:2013-12-01 00:00:00

  • Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

    abstract::Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00216.x

    authors: Escobar C,Barrios V,Jimenez D

    更新日期:2010-10-01 00:00:00

  • Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways.

    abstract:INTRODUCTION:Platelet activation participates in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear. AIMS:This study was designed to test MPs from healthy subject...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12273

    authors: Cheng G,Shan XF,Wang XL,Dong WW,Li Z,Liu XH,Zhang W,Xing K,Chang FJ

    更新日期:2017-08-01 00:00:00

  • Stromal cell derived factor-1 (SDF-1) targeting reperfusion reduces myocardial infarction in isolated rat hearts.

    abstract::Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2011.00301.x

    authors: Jang YH,Kim JH,Ban C,Ahn K,Cheong JH,Kim HH,Kim JS,Park YH,Kim J,Chun KJ,Lee GH,Kim M,Kim C,Xu Z

    更新日期:2012-10-01 00:00:00

  • Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.

    abstract:BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12277

    authors: Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

    更新日期:2017-10-01 00:00:00

  • Bredemolic Acid Improves Cardiovascular Function and Attenuates Endothelial Dysfunction in Diet-Induced Prediabetes: Effects on Selected Markers.

    abstract::Prediabetes is an intermediate hyperglycaemic state which has been associated with cardiovascular dysfunction. However, cardiovascular dysfunction is not only caused by intermediate hyperglycaemia but also endothelial dysfunction, inflammation, and oxidative stress associated with prediabetes. Bredemolic acid (BA), an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2020/1936406

    authors: Akinnuga AM,Siboto A,Khumalo B,Sibiya NH,Ngubane P,Khathi A

    更新日期:2020-02-11 00:00:00

  • Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.

    abstract:Objective:The drug efficacy may differ among different statins, and evidence from head-to-head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid-lowering/increasing effects of 7 different statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus by conducting s...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1155/2020/3987065

    authors: Zhang X,Xing L,Jia X,Pang X,Xiang Q,Zhao X,Ma L,Liu Z,Hu K,Wang Z,Cui Y

    更新日期:2020-04-23 00:00:00

  • Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.

    abstract:BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1755-5922.2011.00297.x

    authors: Bocchi EA,Moura LZ,Issa VS,Cruz F,Carvalho VO,Guimarães GV

    更新日期:2013-04-01 00:00:00

  • Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention.

    abstract:Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2021/8836450

    authors: Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

    更新日期:2021-01-13 00:00:00

  • Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.

    abstract::Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, and end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Recent clinical studies have substantiated the concept of "hyperglycemic...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1527-3466.2007.00038.x

    authors: Yamagishi S,Nakamura K,Matsui T,Ueda S,Noda Y,Imaizumi T

    更新日期:2008-04-01 00:00:00

  • What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?

    abstract::Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00101.x

    authors: Whayne TF Jr

    更新日期:2010-04-01 00:00:00

  • Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials.

    abstract:INTRODUCTION:Statins are known to prevent heart failure (HF). However, it is unclear whether statins as class or type (lipophilic or hydrophilic) improve outcomes of established HF. AIMS:The current meta-analysis was performed to compare the treatment effects of lipophilic and hydrophilic statins on inflammation and c...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12150

    authors: Bonsu KO,Reidpath DD,Kadirvelu A

    更新日期:2015-12-01 00:00:00

  • Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

    abstract:INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12281

    authors: Ascha M,Zhou X,Rao Y,Minai OA,Tonelli AR

    更新日期:2017-10-01 00:00:00

  • TREK-1 K(+) channels in the cardiovascular system: their significance and potential as a therapeutic target.

    abstract::Potassium (K(+) ) channels are important in cardiovascular disease both as drug targets and as a cause of underlying pathology. Voltage-dependent K(+) (K(V) ) channels are inhibited by the class III antiarrhythmic agents. Certain vasodilators work by opening K(+) channels in vascular smooth muscle cells (VSMCs), and...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00227.x

    authors: Goonetilleke L,Quayle J

    更新日期:2012-02-01 00:00:00

  • Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects.

    abstract:OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to t...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2011.00264.x

    authors: Ueda S,Yamagishi S,Matsui T,Noda Y,Ueda S,Jinnouchi Y,Sasaki K,Takeuchi M,Imaizumi T

    更新日期:2012-08-01 00:00:00

  • Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

    abstract:BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12458

    authors: Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

    更新日期:2018-10-01 00:00:00

  • Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

    abstract::The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00065.x

    authors: Grover GJ,Malm J

    更新日期:2008-01-01 00:00:00

  • Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.

    abstract:INTRODUCTION:Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. AIMS:We sought to evaluate the safety and cl...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12111

    authors: LaRue SJ,Garcia-Cortes R,Nassif ME,Vader JM,Ray S,Ravichandran A,Rasalingham R,Silvestry SC,Ewald GA,Wang IW,Schilling JD

    更新日期:2015-04-01 00:00:00

  • The efficacy of glucocorticoids for the prevention of atrial fibrillation, or length of intensive care unite or hospital stay after cardiac surgery: a meta-analysis.

    abstract:AIMS:cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12062

    authors: Liu C,Wang J,Yiu D,Liu K

    更新日期:2014-06-01 00:00:00

  • Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.

    abstract:BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12182

    authors: Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

    更新日期:2016-06-01 00:00:00

  • Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis.

    abstract:BACKGROUND:The systematic review and meta-analysis are to evaluate the effect of t Telmisartan on atrial fibrillation (AF) recurrences in hypertensive patients with paroxysmal AF. METHODS:MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. Random controlled trials (RCTs) were conduct...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12073

    authors: Pan G,Zhou X,Zhao J

    更新日期:2014-08-01 00:00:00

  • Expression of NO Synthase Under Medication with Cyclosporine A, Mycophenolate Mofetil, and Tacrolimus during Development of Transplant Vasculopathy on Rat Cardiac Allograft.

    abstract:OBJECTIVE:The transplant vasculopathy as a sign of chronic graft rejection affects both the epicardial and the intramyocardial arteries of the graft. This is at least partially mediated by NO synthases. The aim of this study was to assess possible protective effects of cyclosporine A (CsA), tacrolimus (FK506), and myco...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12181

    authors: Bogossian H,Frommeyer G,Ninios I,Bandorski D,Seyfarth M,Matzaroglou C,Lemke B,Eckardt L,Zarse M,Kafchitsas K

    更新日期:2016-08-01 00:00:00

  • Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.

    abstract:INTRODUCTION:The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. AIM:This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12108

    authors: Shehata M,Hamza M

    更新日期:2015-04-01 00:00:00

  • Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy.

    abstract::Patients with coronary artery disease (CAD) commonly have varying degrees of coexisting cerebrovascular disease (CVD) and chronic kidney disease (CKD), and proper management is complicated partly because of a lack of unifying guidelines. The aim of this article is to review the current literature and propose the optim...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00087.x

    authors: Notaro LA,Usman MH,Burke JF,Siddiqui A,Superdock KR,Ezekowitz MD

    更新日期:2009-10-01 00:00:00

  • Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.

    abstract:BACKGROUND:Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. METHODS:We ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1755-5922.2010.00185.x

    authors: Krum H,van Veldhuisen DJ,Funck-Brentano C,Vanoli E,Silke B,Erdmann E,Follath F,Ponikowski P,Goulder M,Meyer W,Lechat P,Willenheimer R,behalf of the CIBIS III Investigators.

    更新日期:2011-04-01 00:00:00

  • Epac-Rap1-activated mesenchymal stem cells improve cardiac function in rat model of myocardial infarction.

    abstract:INTRODUCTION:Rap1, a member of Ras superfamily of small GTP-binding proteins, is involved in cardiovascular biology in numerous ways. It is an evolutionary conserved regulator of adhesion, polarity, differentiation and growth. AIMS:Our aim was to analyze Rap1-activated rat bone marrow mesenchymal stem cells (MSCs) for...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12248

    authors: Khan I,Ali A,Akhter MA,Naeem N,Chotani MA,Iqbal H,Kabir N,Atiq M,Salim A

    更新日期:2017-04-01 00:00:00